Saxenda vs Retatrutide: Head-to-Head Efficacy Comparison

Why These Two Drugs Get Compared

Saxenda was one of the first GLP-1 receptor agonists approved specifically for obesity. Retatrutide is the first triple-hormone receptor agonist to reach late-stage development for weight loss. Because both drugs act on the GLP-1 pathway, patients and clinicians naturally ask whether the newer molecule makes the older one obsolete.

The short answer: the efficacy gap is significant, but comparing them requires context. Saxenda (liraglutide 3 mg) earned FDA approval in December 2014 based on the SCALE Obesity and Prediabetes trial, which randomized 3,731 adults without diabetes to liraglutide 3 mg or placebo for 56 weeks [1]. Mean weight loss reached 8.0% with liraglutide versus 2.6% with placebo. At the time, this represented a meaningful advance over orlistat and phentermine-topiramate for many patients.

Retatrutide entered the picture nearly a decade later. Eli Lilly's Phase 2 dose-ranging trial, published in the New England Journal of Medicine in 2023, tested multiple doses in 338 adults with obesity [2]. The 12 mg weekly dose produced 24.2% mean body-weight loss at 48 weeks versus 2.1% with placebo. That magnitude rivals bariatric surgery outcomes, and it exceeded what any single injectable anti-obesity medication had achieved in a controlled trial up to that point.

These are cross-trial comparisons, not head-to-head data. Patient populations, baseline BMI, lifestyle intervention intensity, and trial duration all differed. Still, the threefold difference in weight loss is difficult to dismiss as an artifact of trial design.

Mechanism of Action: One Receptor vs Three

Saxenda activates a single target. It is a GLP-1 receptor agonist that mimics the incretin hormone glucagon-like peptide-1, slowing gastric emptying, reducing appetite, and improving insulin sensitivity [1]. This mechanism drove the first wave of GLP-1-based obesity therapies, including the higher-dose semaglutide (Wegovy) that followed.

Retatrutide works on three receptors simultaneously: GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon [2]. The GLP-1 component suppresses appetite and slows gastric motility, similar to Saxenda. The GIP component appears to enhance fat metabolism and may amplify the GLP-1 effect, a pattern also seen with tirzepatide (Mounjaro/Zepbound), which acts on GLP-1 and GIP but not glucagon. The glucagon component is the distinguishing feature. Glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation, potentially addressing fatty liver disease while contributing additional caloric deficit.

The triple-agonist design is not just additive. Dr. Ania Jastreboff, lead investigator of the retatrutide Phase 2 trial and director of the Yale Obesity Research Center, noted that the glucagon receptor activity "may contribute to the magnitude of weight reduction observed, potentially through increased energy expenditure" [2]. That third receptor pathway may explain the gap between retatrutide's results and those of dual agonists like tirzepatide, which produced 22.5% weight loss at the highest dose in SURMOUNT-1 [3].

Efficacy Data: Parsing the Numbers

The central comparison boils down to specific trial endpoints. Here is what each study reported.

SCALE Obesity and Prediabetes (Saxenda) In Pi-Sunyer et al.'s 56-week study, liraglutide 3 mg daily produced 8.0% mean body-weight loss from baseline [1]. Among completers, 63.2% of Saxenda-treated participants lost at least 5% of body weight compared with 27.1% on placebo. The proportion achieving 10% or greater weight loss was 33.1% versus 10.6% with placebo. These response rates were considered clinically meaningful at the time, particularly given that 5% weight loss is the FDA threshold for metabolic benefit in obesity [4].

Jastreboff et al. Phase 2 (Retatrutide) At the 12 mg dose, participants lost a mean of 24.2% of body weight over 48 weeks [2]. The results were dose-dependent: the 1 mg group lost 8.7%, the 4 mg group lost 17.5%, the 8 mg group lost 22.8%, and the 12 mg group hit 24.2%. At the highest dose, 100% of participants achieved at least 5% weight loss, and 93% exceeded 10%. Nearly 75% of the 12 mg group lost 15% or more.

The placebo-subtracted differences sharpen the contrast. Saxenda's placebo-adjusted loss sits at approximately 5.4 percentage points. Retatrutide at 12 mg delivers approximately 22.1 placebo-adjusted percentage points, roughly four times the net pharmacological effect. Even retatrutide's lowest tested dose (1 mg) produced weight loss comparable to Saxenda's peak dose.

One caveat: the Phase 2 retatrutide trial enrolled only 338 participants, while SCALE enrolled 3,731. Larger Phase 3 trials (the TRIUMPH program) will determine whether retatrutide's efficacy holds up in broader, more diverse populations and over longer durations. Phase 2 trials can overestimate effect sizes due to smaller samples and tighter enrollment criteria.

Cardiometabolic Effects Beyond Weight

Weight loss alone does not capture the full clinical picture. Both drugs affect metabolic markers, but their profiles differ.

Saxenda demonstrated modest improvements in fasting glucose, HbA1c, blood pressure, and lipid panels in SCALE [1]. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity acknowledges liraglutide's cardiovascular risk reduction, citing the LEADER trial that showed a 13% reduction in major adverse cardiovascular events (MACE) in patients with type 2 diabetes treated with liraglutide 1.8 mg [5, 6]. However, LEADER used the diabetes dose, not the obesity dose, so extrapolation requires caution.

Retatrutide's glucagon receptor activity opens a distinct metabolic pathway. In the Phase 2 trial, retatrutide reduced liver fat by a median of 42.9% at the 8 mg dose, as measured by MRI-proton density fat fraction [2]. This effect could prove significant for the roughly 30% of U.S. adults with metabolic dysfunction-associated steatotic liver disease (MASLD) [7]. Glucagon-driven hepatic lipid oxidation may address liver steatosis more directly than GLP-1-only agents, though head-to-head liver-outcome data do not yet exist.

Improvements in HbA1c were also pronounced with retatrutide. Mean HbA1c fell by 0.4 percentage points at the 12 mg dose in the non-diabetic obesity cohort [2]. A separate Phase 2 trial in participants with type 2 diabetes showed HbA1c reductions of up to 2.02 percentage points with retatrutide [8].

Side-Effect Profiles

Gastrointestinal side effects dominate both drugs. Nausea is the most common adverse event.

In SCALE, 40.2% of Saxenda-treated participants reported nausea versus 14.7% on placebo [1]. Diarrhea occurred in 21.2% versus 9.9%. Vomiting affected 16.3% compared with 4.0% on placebo. Most GI events were mild to moderate and peaked during the first four to eight weeks of dose titration. The discontinuation rate due to adverse events was 9.9% with liraglutide versus 3.8% with placebo.

Retatrutide's GI side-effect rates in Phase 2 were broadly similar. Nausea occurred in roughly 25% to 50% of participants across dose groups, diarrhea in 15% to 25%, and vomiting in 10% to 20% [2]. At the 12 mg dose, the discontinuation rate due to adverse events was approximately 6%. The addition of glucagon receptor agonism did not appear to introduce unique hepatotoxicity or clinically significant hyperglycemia in the non-diabetic population, though liver enzyme elevations were monitored closely.

Both drugs carry the FDA class warning for GLP-1 receptor agonists regarding thyroid C-cell tumors observed in rodents, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [4, 9].

Dosing and Administration

Saxenda requires daily subcutaneous injections [4]. The standard titration schedule starts at 0.6 mg daily and increases by 0.6 mg weekly until the maintenance dose of 3 mg is reached, a process that takes approximately five weeks. Daily injection burden is a known barrier to adherence. Some patients find the daily routine manageable; others cite it as a reason for discontinuation.

Retatrutide is administered once weekly by subcutaneous injection [2]. The Phase 2 trial used dose escalation over 12 to 20 weeks depending on the target dose. Weekly dosing mirrors the convenience advantage that semaglutide (Wegovy) demonstrated over Saxenda, and adherence data from semaglutide real-world studies suggest that weekly injections improve persistence compared with daily regimens [10].

The practical difference is seven injections per week versus one. For a 48-week treatment course, that translates to 336 injections with Saxenda versus 48 with retatrutide. This difference alone may influence prescriber and patient preference once retatrutide reaches market.

Availability and Cost Considerations

Saxenda has been commercially available since 2015. Its list price in the United States has historically ranged from $1,300 to $1,500 per month without insurance, though manufacturer savings programs and some commercial insurers reduce out-of-pocket costs. Generic liraglutide for obesity is not yet available, as Novo Nordisk's patents extend through the mid-2020s.

Retatrutide does not have an approved price because it remains investigational. Eli Lilly has not disclosed anticipated pricing. If it follows the trajectory of tirzepatide (Zepbound), which launched at a list price of approximately $1,060 per month, retatrutide's price could fall in a similar range, though the triple-agonist mechanism might command a premium. The Phase 3 TRIUMPH trials are ongoing, and FDA submission timelines remain speculative as of May 2026 [11].

For patients considering Saxenda today, the relevant question is whether to start a currently available medication or wait for a potentially more effective one. The Endocrine Society guideline recommends initiating pharmacotherapy when BMI meets criteria, rather than delaying treatment for future medications [6]. Weight regain during untreated intervals is well-documented, and the metabolic benefits of even modest weight loss (5% to 10%) are clinically meaningful.

Cross-Trial Limitations

No randomized controlled trial has directly compared Saxenda and retatrutide in the same patient population under identical conditions. All comparisons presented here are indirect.

Key differences between the trials that limit direct comparison include baseline BMI (SCALE mean: 38.3 kg/m²; retatrutide Phase 2 mean: 37.3 kg/m²), trial duration (56 weeks vs 48 weeks), sample sizes (3,731 vs 338), and intensity of lifestyle counseling [1, 2]. The SCALE trial enrolled a significant proportion of patients with prediabetes, which may have influenced metabolic outcomes differently than retatrutide's primarily normoglycemic cohort.

The American Association of Clinical Endocrinology (AACE) has emphasized that "cross-trial comparisons should be interpreted with caution, as differences in study design, patient populations, and endpoints can substantially influence observed treatment effects" [12]. With that caveat firmly in place, a 16-percentage-point gap in mean weight loss is large enough that it is unlikely to be fully explained by methodological differences alone.

Who Might Choose Saxenda Today

Despite the efficacy gap, Saxenda retains a role in certain clinical scenarios. Patients who need an FDA-approved medication now, who cannot access or tolerate semaglutide (Wegovy), or who have insurance coverage specifically for liraglutide may reasonably start Saxenda. Patients with a history of pancreatitis should discuss risks with their prescriber, as this concern applies to both GLP-1 agonists [1].

Saxenda also has a longer safety track record. Twelve years of post-marketing surveillance data provide a level of long-term safety confidence that a Phase 2 investigational drug cannot match. For risk-averse patients or clinicians, that track record carries weight.

The practical calculus changes if retatrutide receives FDA approval. At that point, the triple-agonist mechanism, weekly dosing, and substantially greater efficacy may position retatrutide as a preferred option for most patients with obesity. Until then, Saxenda remains a reasonable, if less potent, treatment choice.

The 2023 Endocrine Society guideline states that medication selection should account for "efficacy, side effects, contraindications, drug interactions, cost, and patient preference" [6]. Retatrutide currently satisfies only the efficacy criterion, since it lacks approval, a defined side-effect profile from Phase 3 data, and a known cost.

What the Phase 3 TRIUMPH Program Will Clarify

Eli Lilly's TRIUMPH Phase 3 program includes multiple trials evaluating retatrutide in obesity and type 2 diabetes populations. These trials will establish whether the 24.2% weight loss observed in Phase 2 replicates in larger, more diverse cohorts [11]. They will also provide longer-duration data (likely 52 to 72 weeks), cardiovascular outcome signals, and a more complete adverse-event profile.

If TRIUMPH confirms the Phase 2 efficacy signal with an acceptable safety profile, retatrutide could become the most effective injectable anti-obesity medication available, surpassing not only Saxenda but also semaglutide 2.4 mg (Wegovy, 15.3% weight loss in STEP-1) and tirzepatide 15 mg (Zepbound, 22.5% in SURMOUNT-1) [3, 13]. The retatrutide 12 mg dose at 48 weeks already exceeded tirzepatide's 72-week result numerically, though the shorter trial duration and smaller sample size temper that comparison.

For patients currently weighing their options, the clinically actionable takeaway is this: start an approved therapy that meets your treatment goals now, and discuss switching protocols with your prescriber if and when retatrutide becomes available.